Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Autor: Sabry W; Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada., Wu Y; Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada., Kodad SG; Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Jazyk: angličtina
Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Jul 18; Vol. 29 (7), pp. 5042-5053. Date of Electronic Publication: 2022 Jul 18.
DOI: 10.3390/curroncol29070399
Abstrakt: Plasmablastic lymphoma is a rare subtype of large B-cell lymphoma characterised by an aggressive clinical course with frequent relapses and refractoriness to chemotherapy. It is usually associated with HIV, however, it can also be seen in immunocompetent patients. It has distinct pathological characteristics, such as plasmablastic morphology and lack of CD20 expression. These characteristics pose a clinical and pathological challenge. There is no standard of care established in this entity. In this case report, we described a novel bortezomib-based plasma cell targeted regimen in a HIV-negative patient refractory to chemotherapy.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje